

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this supplemental notice, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this supplemental notice.



YiChang HEC ChangJiang Pharmaceutical Co., Ltd.

宜昌東陽光長江藥業股份有限公司

(A joint stock company incorporated in the People's Republic of China with limited liability)

(Stock Code: 01558)

SUPPLEMENTAL NOTICE OF ANNUAL GENERAL MEETING

Reference is made to the notice of YiChang HEC ChangJiang Pharmaceutical Co., Ltd. (the “**Company**”) dated 24 April 2023 (the “**Notice**”) for the annual general meeting of the Company (the “**AGM**”), which sets out the time and venue of the AGM and contains the resolutions to be considered and approved by the shareholders of the Company at the AGM (the “**Original Resolutions**”).

SUPPLEMENTAL NOTICE IS HEREBY GIVEN that the AGM will be held as originally scheduled at Conference Room, 4/F, Administration Building, Dongyangguang Scientific Park, No. 368 Zhen An Zhong Road, Chang’an County, Dongguan, Guangdong Province, the PRC at 10:00 a.m. on Friday, 2 June 2023 to consider and, if thought fit, to approve in addition to the Original Resolutions, the following resolutions (the “**New Resolutions**”). The New Resolutions were submitted to the AGM by Sunshine Lake Pharma Co., Ltd.* (廣東東陽光藥業有限公司) and its wholly-owned subsidiary, HEC (Hong Kong) Sales Co., Limited (holding in aggregate approximately 51.41% of the issued shares of the Company) in compliance with the laws and the articles of association of the Company. Save as mentioned herein, all information and contents set out in the Notice remain unchanged. Shareholders and potential investors are advised to refer to the Circular (as defined below) for further details in relation to the Continuing Connected Transactions. Unless otherwise defined, capitalized terms used herein shall have the same meanings as those defined in the supplemental circular of the Company dated 17 May 2023 (the “**Circular**”).

ORDINARY RESOLUTIONS

8. **THAT** (a) the execution of the Energy Purchase Framework Agreement (as defined in the Circular) by any director(s) of the Company be and is hereby approved, confirmed and ratified; and (b) the transactions contemplated under the Energy Purchase Framework Agreement and the proposed annual caps for the three years ending 31 December 2023, 2024 and 2025 as set out in the Circular be and are hereby approved.

9. **THAT** (a) the execution of the APIs Purchase Agreement (as defined in the Circular) by any director(s) of the Company be and is hereby approved, confirmed and ratified; and (b) the transactions contemplated under the APIs Purchase Agreement and the proposed annual caps for the three years ending 31 December 2023, 2024 and 2025 as set out in the Circular be and are hereby approved.
10. **THAT** (a) the execution of the Packaging and Production Materials Purchase Framework Agreement (as defined in the Circular) by any director(s) of the Company be and is hereby approved, confirmed and ratified; and (b) the transactions contemplated under the Packaging and Production Materials Purchase Framework Agreement and the proposed annual caps for the three years ending 31 December 2023, 2024 and 2025 as set out in the Circular be and are hereby approved.
11. **THAT** (a) the execution of the Equipment Purchase and Civil Construction Framework Agreement (as defined in the Circular) by any director(s) of the Company be and is hereby approved, confirmed and ratified; and (b) the transactions contemplated under the Equipment Purchase and Civil Construction Framework Agreement and the proposed annual caps for the three years ending 31 December 2023, 2024 and 2025 as set out in the Circular be and are hereby approved.
12. **THAT** (a) the execution of the Entrusted Processing Framework Agreement (as defined in the Circular) by any director(s) of the Company be and is hereby approved, confirmed and ratified; and (b) the transactions contemplated under the Entrusted Processing Framework Agreement and the proposed annual caps for the three years ending 31 December 2023, 2024 and 2025 as set out in the Circular be and are hereby approved.
13. **THAT** (a) the execution of the Equipment Sales Framework Agreement (as defined in the Circular) by any director(s) of the Company be and is hereby approved, confirmed and ratified; and (b) the transactions contemplated under the Equipment Sales Framework Agreement and the proposed annual cap for the year ending 31 December 2023 as set out in the Circular be and are hereby approved.
14. **THAT** (a) the execution of the Entrusted Production and Inspection Services Framework Agreement (as defined in the Circular) by any director(s) of the Company be and is hereby approved, confirmed and ratified; and (b) the transactions contemplated under the Entrusted Production and Inspection Services Framework Agreement and the proposed annual caps for the three years ending 31 December 2023, 2024 and 2025 as set out in the Circular be and are hereby approved.

On behalf of the Board
YiChang HEC ChangJiang Pharmaceutical Co., Ltd.
TANG Xinfa
Chairman

Hubei, the PRC
17 May 2023

Notes:

1. A supplemental form of proxy in respect of the ordinary resolutions numbered 8 to 14 mentioned above (the “**Supplemental Form of Proxy**”) is enclosed with the supplemental notice of the AGM of the Company dated 17 May 2023. The Supplemental Form of Proxy will not affect the validity of any form of proxy duly completed by you in respect of the resolutions set out in the Notice. If you have validly appointed a proxy to attend and act for you at the AGM but do not complete and deliver the Supplemental Form of Proxy, your proxy will be entitled to vote at his/her discretion on the resolutions set out in the supplemental notice of the AGM. If you do not duly complete and deliver the original form of proxy for the AGM but have duly completed and delivered the Supplemental Form of Proxy and validly appointed a proxy to attend and act for you at the AGM, your proxy will be entitled to vote at his/her discretion on the resolutions set out in the Notice.
2. Please refer to the Notice for details in respect of the other resolutions to be passed at the AGM, eligibility for attending the AGM, proxy, registration procedures and other relevant matters in relation to the AGM.

As at the date of this supplemental notice, the Board consists of Mr. JIANG Juncai, Mr. WANG Danjin, Mr. CHEN Yangui and Mr. LI Shuang as executive Directors; Mr. TANG Xinfu as a non-executive Director; and Mr. TANG Jianxin, Ms. XIANG Ling and Mr. LI Xuechen as independent non-executive Directors.